We are advised by Alphamab Oncology that journalists and other readers should disregard the news release, A Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Included in the Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs, issued 13-Nov-2024 over PR Newswire.
source: Alphamab Oncology
《說說心理話》成年人ADHD專注力不足工作會有何問題?嘉賓建議企業4個層面助有關員工► 即睇